Article Text

Download PDFPDF

5 Use of propranolol for infantile haemangiomas: multi-centre experience of 70 cases
  1. Rainer Fortner1,
  2. Marcia Scheller1,
  3. Alexander Wilson2,
  4. Poonamallee Govindaraj2,
  5. Sandeep Ashtekar3,
  6. Dirk Wilson1
  1. 1Noah’s Ark Children’s Hospital, Cardiff, UK
  2. 2Royal Glamorgan Hospital, Pontyclun, UK
  3. 3Royal Gwent Hospital, Newport, UK


Background Propranolol has been used to treat infantile haemangiomas since 2008. Treatment is recommended in lesions complicated by bleeding, ulceration, infection and where breathing, feeding or vision is compromised. We assessed our experience with reference to the proposed Great Ormond Street protocol (2014) which rationalises pretreatment management/investigations.

Methods Retrospective review of electronic records of all children who receiving propranolol for infantile haemangiomas in 3 hospitals in South Wales between 2009 and 2014.

Results 70 children were treated with propranolol. Median age [range] at start of treatment was 4 months [0-24]. Indications for treatment included ocular impairment (40%), cosmesis (29%), ulceration (21%), airway impairment (6%) and miscellaneous (4%). Median length of treatment was 10 months [1–16]. 88.6% of children improved on treatment and only 5 (7%) experienced regrowth on cessation. 12 patients (17.1)% experienced side effects and 7 (10%) had their treatment discontinued or adjusted. Recorded side effects included sleep disturbance (7%), GI upset (3%) and wheeze (3%). All children were examined by a Paediatrician, Neonatologist or Paediatric Cardiologist prior to treatment initiation. 10 (7%) children were noted to have a murmur. ECG and echocardiography were normal in all but one child who was later found to have an arteriovenous malformation rather than haemangioma, requiring embolisation.

Conclusion None of the investigations including echocardiography and blood tests revealed abnormalities contraindicating the administration of propranolol. The selective use of pre-treatment investigations is therefore supported by our data. This review confirms that propranolol is a safe and effective treatment for infantile haemangiomas.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.